Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANAB Stock Summary
Top 10 Correlated ETFs
ANAB
In the News

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio to Participate in Upcoming November Investor Conferences
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.

AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events.

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference. The presentation will be available on Thursday, November 18, 2021, at 3:00 a.m. ET via https://wsw.com/webcast/jeff201/anab/1800252

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.
ANAB Financial details
ANAB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.2 | 0.3 | 2.75 | 2.3 | 0.37 | |
Net income per share | -2.5 | -3.6 | -0.73 | -2.11 | -4.57 | |
Operating cash flow per share | -1.97 | -2.57 | -0.52 | -1.67 | -2.61 | |
Free cash flow per share | -2.01 | -2.6 | -0.54 | -1.67 | -2.63 | |
Cash per share | 17.31 | 13.83 | 14.42 | 19.98 | 15.67 | |
Book value per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
Tangible book value per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
Share holders equity per share | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | |
Interest debt per share | 0.4 | 0.12 | 0.01 | 0.77 | 1.44 | |
Market cap | 1.57B | 439.71M | 586.99M | 953.23M | 872.83M | |
Enterprise value | 1.47B | 270.07M | 336.88M | 479.96M | 820.98M | |
P/E ratio | -25.53 | -4.52 | -29.45 | -16.49 | -6.78 | |
Price to sales ratio | 314.78 | 54.96 | 7.83 | 15.09 | 84.85 | |
POCF ratio | -32.45 | -6.33 | -41.46 | -20.76 | -11.86 | |
PFCF ratio | -31.75 | -6.25 | -39.86 | -20.77 | -11.8 | |
P/B Ratio | 3.24 | 1.09 | 1.48 | 2.67 | 3.33 | |
PTB ratio | 3.24 | 1.09 | 1.48 | 2.67 | 3.33 | |
EV to sales | 293.71 | 33.76 | 4.49 | 7.6 | 79.81 | |
Enterprise value over EBITDA | -24.52 | -2.82 | -17.39 | -8.4 | -7.8 | |
EV to operating cash flow | -30.28 | -3.88 | -23.8 | -10.45 | -11.16 | |
EV to free cash flow | -29.63 | -3.84 | -22.88 | -10.46 | -11.1 | |
Earnings yield | -0.04 | -0.22 | -0.03 | -0.06 | -0.15 | |
Free cash flow yield | -0.03 | -0.16 | -0.03 | -0.05 | -0.08 | |
Debt to equity | 0.05 | 0.07 | 0.05 | 0.8 | 1.33 | |
Debt to assets | 0.04 | 0.07 | 0.05 | 0.45 | 0.57 | |
Net debt to EBITDA | 1.76 | 1.77 | 12.91 | 8.28 | 0.49 | |
Current ratio | 19.89 | 12.79 | 20.01 | 34.4 | 17.16 | |
Interest coverage | -40.39 | -103.2 | 0 | 39.18 | -5.46 | |
Income quality | 0.79 | 0.71 | 0.71 | 0.79 | 0.57 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.11 | 2.01 | 0.25 | 0.34 | 3.56 | |
Research and developement to revenue | 11.24 | 12.42 | 1.07 | 1.56 | 8.63 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.01 | 0.04 | 0 | 0 | |
Capex to revenue | -0.21 | -0.1 | -0.01 | 0 | -0.03 | |
Capex to depreciation | -3.37 | -1.57 | -1.02 | 0.01 | -0.15 | |
Stock based compensation to revenue | 1.99 | 1.55 | 0.15 | 0.24 | 2.66 | |
Graham number | 33.29 | 34.81 | 15.45 | 24.82 | 30.93 | |
ROIC | -0.24 | -1.39 | 0.27 | 0.16 | -0.25 | |
Return on tangible assets | -0.12 | -0.22 | -0.05 | -0.09 | -0.21 | |
Graham Net | 16.4 | 12.71 | 13.69 | 9.53 | 3.3 | |
Working capital | 412.38M | 348.2M | 376.74M | 537.78M | 421.15M | |
Tangible asset value | 486.37M | 405.01M | 396.73M | 356.43M | 262.1M | |
Net current asset value | 411.58M | 347.54M | 376.74M | 267.23M | 98.93M | |
Invested capital | 0.02 | 0.01 | 0 | 0.06 | 0.07 | |
Average receivables | 887.5K | 87K | 0 | 0 | 0 | |
Average payables | 3.88M | 10.84M | 10.23M | 2.98M | 2.26M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 12.7 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 28.74 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.13 | -0.24 | -0.05 | -0.16 | -0.49 | |
Capex per share | -0.04 | -0.03 | -0.02 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.04 | 0.04 | 0.04 | 0.05 | 0.24 | |
Net income per share | -1.18 | -1.31 | -1.15 | -1.18 | -0.94 | |
Operating cash flow per share | -0.92 | -0.76 | -0.86 | -0.63 | -0.38 | |
Free cash flow per share | -0.87 | -0.76 | -0.86 | -0.63 | -0.39 | |
Cash per share | 19.91 | 18.24 | 15.68 | 15.66 | 15.67 | |
Book value per share | 12.95 | 11.93 | 10.79 | 9.81 | 9.31 | |
Tangible book value per share | 12.95 | 11.93 | 10.79 | 9.81 | 9.31 | |
Share holders equity per share | 12.95 | 11.93 | 10.79 | 9.81 | 9.31 | |
Interest debt per share | 0.76 | 0.92 | 0.93 | 0.92 | 0.84 | |
Market cap | 956.81M | 685.62M | 572.54M | 721.65M | 872.83M | |
Enterprise value | 483.54M | 539.8M | 521.06M | 682.94M | 820.98M | |
P/E ratio | -7.35 | -4.73 | -4.4 | -5.39 | -8.26 | |
Price to sales ratio | 946.4 | 706.82 | 470.84 | 558.12 | 128.21 | |
POCF ratio | -37.82 | -32.63 | -23.71 | -40.66 | -81.69 | |
PFCF ratio | -39.98 | -32.54 | -23.63 | -40.55 | -80.37 | |
P/B Ratio | 2.68 | 2.07 | 1.88 | 2.6 | 3.33 | |
PTB ratio | 2.68 | 2.07 | 1.88 | 2.6 | 3.33 | |
EV to sales | 478.28 | 556.5 | 428.51 | 528.19 | 120.59 | |
Enterprise value over EBITDA | -14.39 | -17.51 | -19.95 | -25.5 | -38.13 | |
EV to operating cash flow | -19.11 | -25.69 | -21.58 | -38.48 | -76.83 | |
EV to free cash flow | -20.2 | -25.62 | -21.51 | -38.37 | -75.6 | |
Earnings yield | -0.03 | -0.05 | -0.06 | -0.05 | -0.03 | |
Free cash flow yield | -0.03 | -0.03 | -0.04 | -0.02 | -0.01 | |
Debt to equity | 0.8 | 0.89 | 0.98 | 1.23 | 1.33 | |
Debt to assets | 0.45 | 0.47 | 0.5 | 0.55 | 0.57 | |
Net debt to EBITDA | 14.08 | 4.73 | 1.97 | 1.45 | 2.41 | |
Current ratio | 34.4 | 25.9 | 22.79 | 21.39 | 17.16 | |
Interest coverage | 21.49 | -6.54 | -4.74 | -4.83 | -6.11 | |
Income quality | 0.78 | 0.58 | 0.74 | 0.53 | 0.4 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 5.33 | 10.52 | 6.72 | 6.85 | 1.38 | |
Research and developement to revenue | 26.48 | 23.21 | 17.14 | 17.06 | 3.43 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.05 | 0 | 0 | 0 | 0.02 | |
Capex to revenue | 1.35 | -0.06 | -0.06 | -0.04 | -0.03 | |
Capex to depreciation | 3.55 | -0.1 | -0.14 | -0.09 | -0.29 | |
Stock based compensation to revenue | 3.93 | 7.98 | 5.48 | 4.85 | 0.98 | |
Graham number | 18.55 | 18.74 | 16.74 | 16.17 | 14.01 | |
ROIC | 0.09 | -0.11 | -0.06 | -0.06 | -0.06 | |
Return on tangible assets | -0.05 | -0.06 | -0.05 | -0.05 | -0.04 | |
Graham Net | 9.5 | 7.65 | 5.08 | 3.64 | 3.3 | |
Working capital | 537.78M | 492.63M | 432.94M | 429.38M | 421.15M | |
Tangible asset value | 356.43M | 330.75M | 304.31M | 277.62M | 262.1M | |
Net current asset value | 267.23M | 217.99M | 153.27M | 109.56M | 98.93M | |
Invested capital | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | |
Average receivables | 380.5K | 460.5K | 977K | 1.11M | 590K | |
Average payables | 3.73M | 2.11M | 2.03M | 2.3M | 2.9M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 85.45 | 76.46 | 82.13 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 1.05 | 1.18 | 1.1 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.09 | -0.11 | -0.11 | -0.12 | -0.1 | |
Capex per share | 0.05 | 0 | 0 | 0 | -0.01 |
ANAB Frequently Asked Questions
What is AnaptysBio, Inc. stock symbol ?
AnaptysBio, Inc. is a US stock , located in San diego of Ca and trading under the symbol ANAB
Is AnaptysBio, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $32. The lowest prediction is $32 and the highest is $32
What is ANAB stock prediction ?
What is AnaptysBio, Inc. stock quote today ?
AnaptysBio, Inc. stock price is $21.76 today.
Is AnaptysBio, Inc. stock public?
Yes, AnaptysBio, Inc. is a publicly traded company.